-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2025-520613-31-00
5
2025-10-31
Agitation Associated with Alzheimer’s Disease
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2025-520747-32-00
5
2025-10-29
Mild to moderate Alzheimer’s Disease
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
-
2024-514695-41-00
5
2025-10-17
Ulcerative Colitis
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2023-509175-16-00
5
2025-10-14
Sickle cell disease
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2025-521147-21-00
4
2025-10-08
Lung Cancer
-
2023-509275-17-00
5
2025-10-06
Relapsing multiple sclerosis
-
2024-514822-21-00
5
2025-10-02
Platinum-resistant Ovarian Cancer
-
2023-509131-12-01
4
2025-09-30
Primary Immune Thrombocytopenia
-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2025-520473-40-00
4
2025-09-29
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer